Andrew Cournoyer, RPh, MBA

Pharma Insights

Journeying Through the Past, Present, and Future of Medicare Part D

06/17/2020

Charline Shan, RPh, MPh

Larry Blandford, PharmD—Column Editor

This article explores the beginnings of Medicare Part D and the different dynamics driving current and future change for various stakeholders including the Centers for Medicare & Medicaid Services, plan sponsors,...

This...

06/17/2020

Journal of Clinical Pathways

Pharma Insights

Are Formulary Exclusion Lists Aligned or Contrary to the Shift to Value-Base Care?

09/19/2017

Andrew Cournoyer, RPh, MBA

Larry Blandford, PharmD—Column Editor

The use of formulary exclusion lists continues to expand, with clear impacts to the perception and use of all related medications. Annual updates to these lists suggest a need for careful evaluation by benefit...

The...

09/19/2017

Journal of Clinical Pathways

Pharma Insights

Formulary Exclusion Lists Create Challenges for Pharma and Payers Alike

10/12/2016

Andrew Cournoyer, RPh, MBA

Larry Blandford, PharmD—Column Editor

The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...

The...

10/12/2016

Journal of Clinical Pathways